ISTA Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 2008
Posted on: Thursday, 28 August 2008, 15:01 CDT
IRVINE, Calif., Aug. 28 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. , today announced it will present at the Thomas Weisel Partners Healthcare Conference at 11:30 a.m. Eastern Time on Thursday, September 4, 2008 at the Four Seasons Hotel in Boston, MA.
ISTA's President and Chief Executive Officer, Vicente Anido, Jr., Ph.D., will provide an update on the Company's commercial and clinical progress. To access the live audio broadcast or the subsequent archived recording log onto http://www.istavision.com/. Please connect to the website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.
About ISTA
ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's products and product candidates addressing the $4.7 billion U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company currently markets three products and is developing a strong product pipeline to fuel future growth and market share. The Company's product development and commercialization strategy is to launch a new product every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com/.
ISTA Pharmaceuticals, Inc.
CONTACT: Vince Anido, +1-949-788-5311, vanido@istavision.com, or LaurenSilvernail, +1-949-788-5302, lsilvernail@istavision.com, both of ISTAPharmaceuticals; or Media, Justin Jackson, jjackson@burnsmc.com, or Investors,Juliane Snowden, jsnowden@burnsmc.com, both of Burns McClellan,+1-212-213-0006, for ISTA Pharmaceuticals
Web site: http://www.istavision.com/
Source: PRNewswire-FirstCall
Related Articles
- Takeda Merges With Tap Pharmaceutical Products
- Charles J. Bramlage Named President of Covidien Pharmaceutical Products Business
- TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients With Erosive Esophagitis
- China Biopharma Reaches Agreement With a Regional Pharma to Launch New Pharmaceutical Products
- TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients With Acid-Related Disorders
- Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
- Timothy R. Wright Appointed President of Tyco Healthcare's Pharmaceutical Products and Imaging Solutions Units
- TargetRx to Keynote at 5th Annual Pharmaceutical Product Launches Summit
- Local Pharmaceuticals Production Valued
- Macugen(R) (Pegaptanib Sodium Injection) Named Innovative Pharmaceutical Product Of The Year At The 2005 Pharmaceutical Achievement Awards
 |
 |
User Comments (0)
RSS Feeds